These results are not only consistent with the reports that associate high levels of Wnt-1 and β-Catenin expression with advanced metastatic, hormone-refractory prostate carcinoma [33,34], but they also agree with the suggestion of a functional interaction between the AR and β-Catenin upon co-localization in the nucleus of prostate cancer cells at late stages. The gene discussed is WNT1; the disease is prostate carcinoma.